In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway

Zhu,Hong; Gao,Jun; Wang,Lei; Qian,Ke‑Jian; Cai,Li‑Ping

doi:10.3892/etm.2018.5695

March-2018 Volume 15 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2018 Volume 15 Issue 3

Full Size Image

Article

In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway

Authors:
- Hong Zhu
- Jun Gao
- Lei Wang
- Ke‑Jian Qian
- Li‑Ping Cai
View Affiliations / Copyright

Affiliations: Department of Clinical Medicine, Medical College of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Gynecology, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Pages: 2643-2648
|
Published online on: January 4, 2018

https://doi.org/10.3892/etm.2018.5695
Expand metrics +

Abstract

The aim of the present study was to investigate the mechanism of action by which naringin reverses the resistance of ovarian cancer cells to cisplatin. Semi‑quantitative reverse transcription polymerase chain reaction (RT‑PCR) and western blotting assays were used to detect the effects of different concentrations of naringin on the expressions of nuclear factor (NF)‑κB and P‑glycoprotein (P‑gp) in the SKOV3/CDDP cell line. Small interfering RNA (siRNA) targeting NF‑κB was designed and synthesized to silence NF‑κB, and recombinant plasmid vectors overexpressing NF‑κB were constructed to transfect cells. RT‑qPCR and western blotting assays were subsequently performed to detect the effects of NF‑κB on the expression of P‑gp at the mRNA and protein levels. Naringin was added to the NF‑κB‑overexpressing SKOV3/CDDP cells and cultured for 48 h, followed by the detection of the expression of P‑gp. RT‑PCR and western blotting results demonstrated that the gene and protein expressions of NF‑κB and P‑gp were significantly decreased in a dose‑dependent manner by naringin treatment (P<0.05). In cells overexpressing NF‑κB, P‑gp expression was significantly elevated (P<0.05), and the expression of P‑gp was significantly decreased when NF‑κB was silenced (P<0.05). Treatment with naringin was able to significantly ameliorate the NF‑κB‑induced overexpression of P‑gp (P<0.05). These results indicate that naringin is able to inhibit the expression of NF‑κB and P‑gp in SKOV3/CDDP cells. Such an inhibitory effect may increase gradually with concentration, and is associated with blockade of the NF‑κB signaling pathway. This pathway may represent one of the mechanisms of action by which Naringin reverses resistance to platinum‑based agents in ovarian cancer cells.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Eoh KJ, Lee JY, Yoon JW, Nam EJ, Kim S, Kim SW and Kim YT: Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery. Oncotarget. 8:37807–37816. 2017. View Article : Google Scholar : PubMed/NCBI
3	Jessmon P, Boulanger T, Zhou W and Patwardhan P: Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 17:427–437. 2017. View Article : Google Scholar : PubMed/NCBI
4	Poveda Velasco A, Casado Herráez A, Cervantes Ruipérez A, Gallardo Rincón D, García García E, González Martín A, López García G, Mendiola Fernández C and Ojeda González B; GEICO Group, : Treatment guidelines in ovarian cancer. Clin Transl Oncol. 9:308–316. 2007. View Article : Google Scholar : PubMed/NCBI
5	Choi M, Fuller CD, Thomas CR Jr and Wang SJ: Conditional survival in ovarian cancer: Results from the SEER dataset 1988–2001. Gynecol Oncol. 109:203–209. 2008. View Article : Google Scholar : PubMed/NCBI
6	Birt DF, Hendrieh S and Wang W: Dietary agents in cancer prevention: Flavonoids and isoflavonoids. Pharmacol Thera. 90:157–177. 2001. View Article : Google Scholar
7	Song SH, Hu X, Xiong YQ and Cai LP: Effects of Naringin on expression of COX-2 mRNA and protein in human ovarian cancer cell line SKOV3. Chin J Clin Pharmacol Ther. 18:271–276. 2013.(In Chinese).
8	Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ and Gately K: Targeting nuclear factor kappaB to overcome resistance to chemotherapy. Front Oncol. 3:1202013. View Article : Google Scholar : PubMed/NCBI
9	Goff B: Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 55:36–42. 2012. View Article : Google Scholar : PubMed/NCBI
10	Mucciolk M and Benencia F: Toll-like receptors in ovarian cancer as targets for immunotherapies. Front Immunol. 5:3412014.PubMed/NCBI
11	Bookman MA: First 1ine chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol. 55:96–113. 2012. View Article : Google Scholar : PubMed/NCBI
12	Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, et al: Platinum versus platinum, Combination chemotherapy in platinum-sensitive recurrent ovarian cancer: A meta-analysis using individual patient data. Ann Onco1. 24:3028–3034. 2013. View Article : Google Scholar
13	Schwab CL, English DP, Roque DM and Santin AD: Taxanes: Their impact on gynecologic malignancy. Anticancer Drugs. 25:522–535. 2014. View Article : Google Scholar : PubMed/NCBI
14	Pellicciotta I, Yang CP, Venditti CA, Goldberg GL and Shahabi S: Response to microtubμle-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell Int. 13:332013. View Article : Google Scholar : PubMed/NCBI
15	Sorbe B, Graflund M, Nygren L and Horvath G: A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity proftes. Oncol Lett. 5:1140–1148. 2014. View Article : Google Scholar
16	Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 89:207–216. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Han A, Chen E, Singh RK, Chichester CO, Moore RG, Singh AP and Vorsa N: The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol. 46:1924–1934. 2015. View Article : Google Scholar : PubMed/NCBI
18	Li J, Wang Y, Lei JC, Hao Y, Yang Y, Yang CX and Yu JQ: Sensitisation of ovarian cancer cells to cisplatin by flavonoids from Scutellaria barbata. Nat Prod Res. 28:683–689. 2014. View Article : Google Scholar : PubMed/NCBI
19	Salmah Y, Hasanah MG and Gan SK: Naringin content in local citrus fruits. Food Chem. 37:113–121. 1990. View Article : Google Scholar
20	You Q and Wu K: Naringin cardiovascular pharmacological effects. Guangdong Med J. 31:3006–3008. 2010.
21	Meiyanto E, Hermawan A and Anindyajati: Natural products for cancer-targeted therapy: Citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 13:427–436. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wang L and Cai LP: Reversal of drug resistance and reversal mechanism of human ovarian cancer resistant SKOV3/DDP cells by naringin. J Clin Oncol. 21:598–602. 2016.
23	Dharmapuri G, Doneti R, Philip GH and Kalle AM: Celecoxib sensitize simatinib-resistant K562 cell stoimatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways. Leuk Res. 39:696–701. 2015. View Article : Google Scholar : PubMed/NCBI
24	Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M and Zabel M: MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013:2417632013. View Article : Google Scholar : PubMed/NCBI
25	Januchowski R, Sterzyńska K, Zaorska K, Sosińska P, Klejewski A, Brązert M, Nowicki M and Zabel M: Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 9:652016. View Article : Google Scholar : PubMed/NCBI
26	Abraham J, Salama NN and Azab AK: The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymphoma. 156:26–33. 2015. View Article : Google Scholar
27	Tomiyasu H, Watanabe M, Sugita K, Goto-Koshino Y, Fujino Y, Ohno K, Sugano S and Tsujimoto H: Regμlations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines. Anticancer Res. 33:5317–5323. 2013.PubMed/NCBI
28	Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE and Maia RC: Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom. 80:158–166. 2011. View Article : Google Scholar : PubMed/NCBI
29	Allen CT, Ricker JL, Chen Z and Van Waes C: Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck. 29:959–971. 2007. View Article : Google Scholar : PubMed/NCBI
30	Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, et al: High expression of Rel A/P65is associated with activation of nuclear factor-kappa B-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 97:523–530. 2007. View Article : Google Scholar : PubMed/NCBI
31	Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, et al: FAS and NF-κB signaling modulate dependence of lung cancers on mutant EGFR. Nature. 471:523–526. 2011. View Article : Google Scholar : PubMed/NCBI
32	Napetschnig J and Wu H: Molecular basis of NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013. View Article : Google Scholar : PubMed/NCBI
33	Cho HH, Song JS, Yu JM, Yu SS, Choi SJ, Kim DH and Jung JS: Differential effect of NF-kappaB activity on beta-catenin/Tcf pathway in various cancer cells. FEBS Lett. 582:616–622. 2008. View Article : Google Scholar : PubMed/NCBI